...damage repair, with programs in Phase I and Phase II testing. Merck obtained molecules targeting ATR...
...new ways of inducing synthetic lethality has raised interest in other targets, such as the ATR...
...does not include the biotech’s two most advanced programs, which target ATR and POLQ. The ATR...

...synthetic lethality program ATG-018, which is an ATR...
...Tumor necrosis factor receptor superfamily member 9ATR (FRP1...

...Sandler. Repare plans to start a Phase I/II trial next quarter of its lead program, ATR...
...Targets ATM - Ataxia telangiectasia mutated ATR (FRP1) - Ataxia telangiectasia and Rad3 related (ATR...

...Senhwa synthetic lethal compound CX-5461 from Senhwa Biosciences Inc. (TPEx:6492) activates the replication stress sensor ATR...
...CX-5461 exhibits synthetic lethality with PARP inhibition in high-grade serous ovarian cancer (HGSOC) cells. The ATR...
...PCBP1 activity could serve as a predictor of patient response to checkpoint inhibitors. Targets ATR (FRP1...

...such as BRCA1, has launched a search for similarly potent inhibitor-mutation pairings (see “Following PARP, ATR...
...Phase I testing for multiple solid cancers. Repare plans to test its lead program, preclinical ATR...
...develop and commercialize Repare’s POLQ inhibitor in Japan and other select Asian territories. Targets ATR (FRP1...

...already gained traction, such as PARP and ATR ( No. 1058 ) (see “Following PARP, ATR...
...on a radioligand therapy ( No. CT159 ) (see “Radiotherapy Blasts Forward” ). Targets ATR (FRP1...

...that interact with PARP inhibition and novel DNA damage repair targets, including members of the ATR...
...outside of DNA damage repair pathways (see “Broadening the PARP Playing Field” ; “Following PARP, ATR...
...of the mRNA processing complex for identifying novel therapeutic targets for lineage-selective killing. Targets ATR (FRP1...

...$17 million. Connecticut Innovations and Godfrey Capital participated in the round. The company’s lead program, ATR-04...
...MaveriX is eligible to receive up to $138 million in milestone payments from Sotio. BioCentury Staff Azitra Inc. ATR-04 MVX-5005 MaveriX...

...the bulk of the funds will go towards clinical and preclinical testing, Segal said. Repare’s ATR...
...behind that. The funds will take Repare through the initial clinical data readouts on its ATR...
...joined Repare’s board, as did OrbiMed’s David Bonita. Targets: ATM - Ataxia telangiectasia mutated; ATR (FRP1...